CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

How does the first CRISPR treatment work? Can biotech rebound? And when is $300 million not $300 million? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. With the ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

Expertise from Forbes Councils members, operated under license. Opinions expressed are those of the author. In the world of biopharmaceutical innovation, 2024 will be remembered as CRISPR’s breakout ...

“It’s a little scary, quite honestly,” says Dr. Jennifer Doudna, who helped develop CRISPR gene-editing technology. By David Marchese It’s entirely possible, maybe even likely, that during some slow ...

Clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated (Cas) proteins are core components of fast-evolving therapeutic gene editing tools. Scientists have used CRISPR ...

We expect CRISPR Therapeutics CRSP to surpass expectations when it reports second-quarter 2024 results next month. Let’s see how things have shaped up for the quarter to be reported. CRISPR ...

Investors in CRISPR Therapeutics AG (Symbol: CRSP) saw new options become available today, for the June 27th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ...